AAIC 2026

Alzheimer’s trials face growing enrollment complexity, evolving biomarker requirements, tighter eligibility criteria, and increasing expansion beyond anti-amyloid and anti-tau approaches into immunomodulatory investigational products.

Flourish Research has deep experience in Alzheimer’s disease clinical trials across our network of wholly owned sites.

• Experience with nearly 200 Alzheimer’s disease and dementia studies
• Alzheimer’s experience across disease-modifying therapies and prevention cohorts
• Onsite raters
• Extensive biomarker experience, including blood-based biomarkers and CSF assays
• Genetic testing capabilities, including APOE genotyping
• Advanced PET imaging capabilities

Our principal investigators will be at AAIC 2026. If you’re attending, we’d love to connect and talk about your next trial.